Lactobacillus reuteri
Lactobacillus reuteri (now Limosilactobacillus reuteri) is a probiotic species whose effects depend on the strain; several strains have their own pages: DSM 17938 (BioGaia Protectis), ATCC PTA 6475 (BioGaia Osfortis), RC-14 taken with L. rhamnosus GR-1, and DSM 17648, a non-viable preparation sold as Pylopass. For DSM 17938, pooled individual data from four placebo-controlled trials showed less crying in breastfed infants with colic but no clear effect in formula-fed infants; it also raised weekly bowel movements in one adult trial, while two child abdominal pain trials disagreed. For ATCC PTA 6475, the strain alone slowed shin bone loss in one trial in women aged 75 to 80, but in a larger 2-year trial in early menopause, the strain given with vitamin D did no better than a vitamin D placebo. NCIMB 30242 lowered LDL cholesterol, a blood marker, in one maker-funded trial. Results for one strain do not carry over to another.
Benefits
Infant digestive comfort: less crying in breastfed babies (DSM 17938)
A pooled analysis of individual data from four double-blind trials (345 infants with colic) found that infants given DSM 17938 cried and fussed about 25 minutes less per day than with placebo at day 21 and were about 1.7 times as likely to reach treatment success. The effect was large in breastfed infants and not significant in formula-fed infants. Discuss any infant probiotic with a pediatrician.
Bowel movement frequency in adults (DSM 17938)
In a 4-week double-blind trial in 40 adults with functional constipation, DSM 17938 raised weekly bowel movements by 2.6 versus 1.0 with placebo, reaching 5.28 versus 3.89 a week. Stool consistency, the secondary outcome, did not differ between groups. Other adult trials of this strain are described on its own page.
Abdominal comfort in school-age children (DSM 17938)
In 101 children aged 6 to 15 with functional abdominal pain, 4 weeks of DSM 17938 cut pain episodes to 1.9 versus 3.6 a week and lowered pain intensity versus placebo. In a second trial in 54 children, pain eased in both the probiotic and placebo groups and the difference between groups was not significant.
Bone density in women aged 75 to 80, not in early menopause (ATCC PTA 6475)
In 90 women aged 75 to 80 with low bone density, 10 billion CFU a day of ATCC PTA 6475 alone, without vitamin D, cut 12-month loss of shin volumetric bone density to 0.83% versus 1.85% with placebo; hip and spine density did not differ significantly. In 239 women aged 50 to 60, neither dose, given with vitamin D, slowed bone loss over 2 years compared with a vitamin D placebo. BioGaia co-funded both trials.
LDL cholesterol in a 9-week capsule trial (NCIMB 30242)
In a 9-week double-blind trial in which 127 adults with high cholesterol completed the study, NCIMB 30242 capsules lowered LDL cholesterol by 11.6 percent and total cholesterol by 9.1 percent versus placebo; HDL cholesterol and triglycerides did not change. These are blood markers, not heart outcomes. The maker, Micropharma, funded the trial, and its cofounders and an employee wrote the paper.
Gum and plaque scores in a two-strain lozenge trial
In a randomized placebo-controlled trial in 45 pregnant women with gum inflammation, lozenges with ATCC PTA 5289 and DSM 17938, taken twice daily for about 7 weeks until birth, led to lower gingival index and plaque index scores than placebo. It was one small trial, used alongside normal oral hygiene.
Mechanism of action
Reuterin and vitamin B12 genes
L. reuteri can turn glycerol into reuterin, a broad-spectrum antimicrobial compound. Genome work on the type strain JCM 1112 found a 58-gene cluster for making reuterin and vitamin B12 (cobalamin) and showed glycerol conversion to reuterin. Whether this contributes to the effects seen in human trials has not been shown, and it should not be relied on as a vitamin source.
Bile salt hydrolase activity
NCIMB 30242 has bile salt hydrolase activity, which breaks apart bile acids in the gut. In the 9-week capsule trial, blood deconjugated bile acids rose and plant sterols such as campesterol and sitosterol fell by about 34 to 42 percent, which the authors read as reduced sterol absorption.
Clinical trials
Individual participant data meta-analysis of 4 double-blind randomized placebo-controlled trials of L. reuteri DSM 17938 given orally to infants with colic, with crying and fussing time and treatment success at 21 days; several authors report BioGaia fees outside the submitted work. (Sung et al. 2018, Pediatrics)
345 infants with colic (174 probiotic, 171 placebo), breastfed and formula-fed.
At day 21 the probiotic group had 25.4 fewer minutes of crying or fussing than placebo (95% CI -47.3 to -3.5) and was 1.7 times as likely to reach treatment success. Effects were large in breastfed infants (number needed to treat 2.6) but not significant in formula-fed infants, where the authors found too little data to draw conclusions.
Randomized double-blind placebo-controlled trial of L. reuteri DSM 17938 or matching placebo for 4 weeks; the primary outcome was the rise in weekly bowel movements and the secondary outcome was stool consistency. (Ojetti et al. 2014, J Gastrointestin Liver Dis)
40 adults with functional constipation (Rome III).
Weekly bowel movements rose by 2.6 with L. reuteri vs 1.0 with placebo (p=0.046), reaching 5.28 vs 3.89 a week. Stool consistency did not differ.
Randomized double-blind placebo-controlled trial of L. reuteri DSM 17938 for 4 weeks plus 4 weeks follow-up, with pain rated daily on the Hicks faces scale; NCT01180556. (Weizman et al. 2016, J Pediatr)
101 children aged 6 to 15 with functional abdominal pain (Rome III); 93 analyzed.
Pain episodes fell to 1.9 vs 3.6 a week (P<.02) and pain intensity to 4.3 vs 7.2 on the Hicks faces scale (P<.01) versus placebo. No difference in school absence or other symptoms, except less perceived bloating.
Randomized placebo-controlled trial at three university hospitals in Greece, Slovenia and Poland: 2x10^8 CFU of L. reuteri DSM 17938 or placebo for 4 weeks, with follow-up to 8 weeks. (Maragkoudaki et al. 2017, Acta Paediatr)
54 children with functional abdominal pain (Rome III), mean age 9.1 years (27 per group).
Pain frequency and intensity fell from baseline in both the L. reuteri and placebo groups at 4 and 8 weeks, and the difference between groups was not significant. Pain reliever use and school or parental work absences fell only within the L. reuteri group, again without a significant difference from placebo. No side effects were recorded.
Randomized, double-blind, placebo-controlled trial of L. reuteri ATCC PTA 6475, 10 billion CFU a day as a powder in stick packs with no vitamin D (placebo was maltodextrin), for 12 months; primary outcome was relative change in tibia total volumetric BMD; funded by BioGaia AB, the Swedish Research Council and Sahlgrenska University Hospital; NCT02422082. (Nilsson et al. 2018, J Intern Med)
90 women aged 75 to 80 with a DXA T-score of -1 or lower at the spine or hip, osteoporosis excluded; 70 completed.
Tibia total volumetric BMD fell 0.83% with L. reuteri versus 1.85% with placebo in the intention-to-treat analysis (mean difference 1.02%, 95% CI 0.02 to 2.03). The secondary bone outcomes, including hip and spine areal BMD, showed similar but smaller effects that were not statistically significant in the intention-to-treat population; trabecular bone volume fraction was significant only in per-protocol and sensitivity analyses. Adverse events did not differ between groups.
Randomized, double-blind, placebo-controlled single-center trial in Sweden of 1 or 10 billion CFU a day (0.5 or 5 billion CFU twice daily) for 2 years; all capsules, placebo included, had 200 IU vitamin D3 (400 IU a day), so the high dose matched the Osfortis daily formula and was compared with vitamin D alone; funded by BioGaia AB, the Swedish Research Council and Sahlgrenska University Hospital, with randomization done by BioGaia; NCT04169789. (Gregori et al. 2024, JAMA Netw Open)
239 women aged 50 to 60 (median 55) in early menopause (80 high dose, 80 low dose, 79 placebo).
The primary outcome was null: tibia total vBMD fell in all groups with no difference from placebo for either dose. Hip and spine vBMD, the turnover markers CTX and PINP, and other predefined outcomes also did not differ. A prespecified analysis found an interaction between body mass index and treatment at 2 years. No treatment-related serious adverse events occurred.
Randomized, double-blind, placebo-controlled, parallel-arm multicenter trial of L. reuteri NCIMB 30242 capsules or placebo capsules for 9 weeks; the primary outcome was LDL cholesterol versus placebo; supported by Micropharma Limited, two authors being its cofounders and shareholders and the third its employee and shareholder. (Jones et al. 2012, Eur J Clin Nutr)
127 adults with high cholesterol completed the study.
Versus placebo, LDL cholesterol fell 11.64 percent, total cholesterol 9.14 percent, non-HDL cholesterol 11.30 percent and apolipoprotein B-100 8.41 percent. HDL cholesterol and triglycerides did not change. hs-CRP fell by 1.05 mg/L and fibrinogen by 14.25 percent, blood deconjugated bile acids rose and plant sterol levels fell, suggesting reduced sterol absorption.
Randomized placebo-controlled trial of lozenges with at least 10^8 CFU each of L. reuteri ATCC PTA 5289 and DSM 17938, or placebo lozenges, taken twice daily from the third trimester until birth (about 7 weeks). (Schlagenhauf et al. 2016, J Clin Periodontol)
45 healthy pregnant women with pregnancy gingivitis (24 L. reuteri, 21 placebo).
Gingival index and plaque index did not differ at baseline. After birth, both were significantly lower in the L. reuteri group than with placebo (p < 0.0001). Blood TNF-alpha was lower in the L. reuteri group at baseline and no longer differed at the end. The authors described the lozenges as a possible adjunct for gum care in pregnancy.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Lactobacillus reuteri
What is Lactobacillus reuteri used for?
Uses depend on the strain. DSM 17938 has the most research, for crying time in breastfed infants with colic and for bowel movement frequency in one adult trial. ATCC PTA 6475 was studied for bone density in women: alone it slowed shin bone loss in one trial in women aged 75 to 80, while with vitamin D it did no better than a vitamin D placebo in a 2-year trial in early menopause. NCIMB 30242 capsules were studied for LDL cholesterol, and lozenges with ATCC PTA 5289 and DSM 17938 for gum and plaque scores.
Has L. reuteri been studied in crying, fussy babies?
Yes, for strain DSM 17938. In a pooled analysis of four placebo-controlled trials in infants with colic, breastfed babies cried and fussed less, while the effect in formula-fed babies was not clear. Use infant-appropriate products and check with a pediatrician.
What is the recommended dosage of Lactobacillus reuteri?
There is no single dose because it depends on the strain and product: drops for infants, 2x10^8 CFU a day in one child trial, 10 billion CFU a day of ATCC PTA 6475 in the bone trials, daily capsules in the cholesterol trial, and lozenges with at least 100 million CFU of each strain twice daily in the gum trial. Follow the specific product's labeling.
Is Lactobacillus reuteri safe, and does it have side effects?
The cited trials reported few harms: no side effects in one child trial, adverse events no different from placebo in a 12-month bone trial, and no treatment-related serious adverse events in a 2-year trial. NCCIH notes a greater risk of harm from probiotics in people with severe illnesses or weakened immunity, and in premature infants, so ask a doctor first in those cases.
Are all L. reuteri strains the same?
No. DSM 17938 (BioGaia Protectis), ATCC PTA 6475 (BioGaia Osfortis), RC-14 (taken with L. rhamnosus GR-1) and DSM 17648 (a non-viable preparation sold as Pylopass) each have their own pages, and a result for one strain does not show what another does. Check the strain named on the label.
What is Lactobacillus reuteri?
Lactobacillus reuteri (now Limosilactobacillus reuteri) is a probiotic species whose effects depend on the strain; several strains have their own pages: DSM 17938 (BioGaia Protectis), ATCC PTA 6475 (BioGaia Osfortis), RC-14 taken with L. rhamnosus GR-1, and DSM 17648, a non-viable preparation sold as Pylopass.
Does Lactobacillus reuteri interact with any medications?
Possible interactions include: Antibiotics: none of the cited trials tested how to time a probiotic around an antibiotic dose; ask your pharmacist. Cholesterol-lowering medicines: NCIMB 30242 was studied for LDL cholesterol, so tell your prescriber before adding it to a statin or other lipid medicine. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Lactobacillus reuteri?
NutraSmarts rates the evidence for Lactobacillus reuteri as Moderate (3 out of 5). It is backed by 8 study summaries and 12 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(12 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Long-Term Efficacy of Limosilactobacillus reuteri DSM17938 in the Prevention of Functional Abdominal Pain Disorders. Nutrients. 2026;18(4):687. doi: 10.3390/nu18040687.PubMedUsed to support: Ten-year follow-up of 200 children from an earlier randomized trial of DSM 17938 in infancy. Functional abdominal pain at age 10 was diagnosed in 13.1 percent of the former probiotic group and 80.2 percent of the former placebo group. The authors note the follow-up was observational with 57.2 percent attrition and describe the finding as an association, not proof of cause.
- Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis. Pediatrics. 2018;141(1):e20171811. doi: 10.1542/peds.2017-1811.PubMedUsed to support: Individual participant data meta-analysis of 4 double-blind trials (345 infants with colic): DSM 17938 reduced crying and fussing time versus placebo (25.4 minutes per day at day 21) and raised the chance of treatment success (incidence ratio 1.7). The effect was large in breastfed infants and not significant in formula-fed infants.
- Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 2012;66(11):1234-41. doi: 10.1038/ejcn.2012.126.PubMedUsed to support: Randomized, double-blind, placebo-controlled 9-week trial of NCIMB 30242 capsules in hypercholesterolemic adults (127 completed): LDL cholesterol fell 11.64 percent, total cholesterol 9.14 percent, non-HDL cholesterol 11.30 percent and apoB-100 8.41 percent versus placebo; HDL and triglycerides did not change. A blood lipid outcome, not a cardiovascular outcome trial. Supported by Micropharma Limited; two authors were its cofounders and shareholders and the third its employee and shareholder (journal page).
- Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT. J Clin Periodontol. 2016;43(11):948-954. doi: 10.1111/jcpe.12606.PubMedUsed to support: Randomized placebo-controlled trial in 45 pregnant women with pregnancy gingivitis: lozenges with L. reuteri ATCC PTA 5289 and DSM 17938 twice daily for about 7 weeks gave significantly lower gingival index and plaque index than placebo after birth.
- The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointestin Liver Dis. 2014;23(4):387-91. doi: 10.15403/jgld.2014.1121.234.elr.PubMedUsed to support: Double-blind placebo-controlled trial in 40 adults with functional constipation given L. reuteri DSM 17938 or placebo for 4 weeks: weekly bowel movements rose by 2.6 versus 1.0 with placebo (p=0.046), reaching 5.28 versus 3.89 a week; stool consistency did not differ.
- Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. J Pediatr. 2016;174:160-164.e1. doi: 10.1016/j.jpeds.2016.04.003.PubMedUsed to support: Randomized double-blind placebo-controlled trial in 101 children aged 6 to 15 with functional abdominal pain: after 4 weeks of DSM 17938, pain episodes were 1.9 versus 3.6 a week and pain intensity 4.3 versus 7.2 on the Hicks faces scale; school absence and other symptoms did not differ except less perceived bloating.
- Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr. 2017;106(11):1857-1862. doi: 10.1111/apa.13992.PubMedUsed to support: Randomized placebo-controlled trial in 54 children with functional abdominal pain given 2x10^8 CFU of DSM 17938 or placebo for 4 weeks: pain frequency and intensity fell in both groups, and the difference between groups was not significant. No side effects were recorded.
- Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. J Intern Med. 2018;284(3):307-317. doi: 10.1111/joim.12805.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 90 women aged 75 to 80 with low bone mineral density (70 completed): 10 billion CFU a day of L. reuteri ATCC PTA 6475 for 12 months reduced loss of tibia total volumetric BMD versus placebo (-0.83% vs -1.85%, mean difference 1.02%, 95% CI 0.02 to 2.03) in the intention-to-treat analysis. Secondary bone outcomes showed smaller effects that were not significant in the intention-to-treat population. Adverse events did not differ. The strain was given as a powder without vitamin D and the placebo was maltodextrin. Funded by BioGaia AB, the Swedish Research Council and Sahlgrenska University Hospital; NCT02422082.
- Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2415455. doi: 10.1001/jamanetworkopen.2024.15455.PubMedUsed to support: Randomized, double-blind, placebo-controlled 2-year trial in 239 early postmenopausal women aged 50 to 60: 0.5 or 5 billion CFU twice daily, in capsules with 200 IU vitamin D3 that the placebo also contained, had no effect on tibia total volumetric BMD (primary outcome), hip or spine BMD, or bone turnover markers versus placebo. A prespecified analysis found an interaction between BMI and treatment at 2 years. Funded by BioGaia AB, the Swedish Research Council and Sahlgrenska University Hospital; NCT04169789.
- Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013;5(8):3062-73. doi: 10.3390/nu5083062.PubMedUsed to support: Identifies L. reuteri DSMZ 17648 as Pylopass (Lonza) and, in its spray-dried form, as dead cell material. Single-blinded placebo-controlled pilot study in 22 asymptomatic adults with H. pylori. Cited here only to name the strain; its own page covers its results.
- Comparative genome analysis of Lactobacillus reuteri and Lactobacillus fermentum reveal a genomic island for reuterin and cobalamin production. DNA Res. 2008;15(3):151-61. doi: 10.1093/dnares/dsn009.PubMedUsed to support: Genome study (lab work, not a human trial): the type strain L. reuteri JCM 1112 carries a 58-gene cluster for making reuterin, a broad-spectrum antimicrobial compound made from glycerol, and cobalamin (vitamin B12), and NMR showed it converts glycerol to reuterin.
- Probiotics: What You Need To Know. NCCIH (NIH). 2019;Online fact sheet, last updated August 2019; accessed 2026-10-31..SourceUsed to support: Not PubMed-indexed; US government fact sheet. States that the risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems, and that severe or fatal infections have been reported in premature infants given probiotics. It gives no guidance on timing probiotics around antibiotics.